QS Investors’s Supernus Pharmaceuticals SUPN Stock Holding History

QS Investors’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-13,036	Closed	-$272K	–	1252
2020 Q3	$272K	Sell	13,036 -10,658	-45%	-$242K	﹤0.01%	962
2020 Q2	$563K	Hold	23,694	–	–	0.01%	876
2020 Q1	$427K	Sell	23,694 -2,700	-10%	-$56.7K	0.01%	883
2019 Q4	$626K	Hold	26,394	–	–	0.01%	875
2019 Q3	$726K	Hold	26,394	–	–	0.01%	859
2019 Q2	$874K	Hold	26,394	–	–	0.01%	835
2019 Q1	$925K	Hold	26,394	–	–	0.01%	840
2018 Q4	$877K	Hold	26,394	–	–	0.01%	797
2018 Q3	$1.33M	Hold	26,394	–	–	0.01%	740
2018 Q2	$1.58M	Buy	26,394 +3,107	+13%	+$161K	0.02%	663
2018 Q1	$1.07M	Buy	23,287 +10	+0%	+$417	0.01%	768
2017 Q4	$928K	Buy	23,277 +73	+0.3%	+$2.88K	0.01%	818
2017 Q3	$928K	Hold	23,204	–	–	0.01%	826
2017 Q2	$1M	Buy	+23,204	New	+$826K	0.01%	782
2016 Q2	–	Sell	-19,300	Closed	-$294K	–	2059
2016 Q1	$294K	Buy	19,300 +1,100	+6%	+$14.4K	﹤0.01%	1005
2015 Q4	$245K	Buy	+18,200	New	+$282K	﹤0.01%	1052

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

ACM

Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return

QS Investors's SUPN Position: Q4 2020 in Review

QS Investors sold out of Supernus Pharmaceuticals (SUPN) in Q4 2020, closing a stake of 13,036 shares — an estimated $272K sold.

QS Investors first reported a position in SUPN in Q4 2015 and held it in 16 quarters. The position peaked at $1.58M in Q2 2018. 225 funds tracked by Wall St. Rank hold SUPN as of Q4 2020.

QS Investors reported no remaining Supernus Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
QS Investors sold 13,036 Supernus Pharmaceuticals shares in Q4 2020, an estimated $272K.
QS Investors first reported a position in Supernus Pharmaceuticals in Q4 2015 and held it in 16 quarters.
QS Investors's Supernus Pharmaceuticals position peaked at $1.58M in Q2 2018.
225 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2020.

Based on QS Investors's 13F filing for Q4 2020, filed 10 Feb 2021.